NOV 26, 2012
Oxigene, Inc. announced data from a Phase 2 trial of Zybrestat (fosbretabulin) showing transient reduction in both polyp activity and amount of subretinal fluid in patients with polypoidal choroidal vasculopathy (PCV).
The randomized, double-masked, multi-center study of 20 Asian patients showed the treated group experienced more transient reduction in polyp activity and subretinal fluid than placebo (P=0.032). There were no drug-related serious adverse events.
"We believe that Zybrestat has potential as a treatment for PCV and other ocular diseases involving abnormal blood vessel formation, such as age-related macular degeneration, and could potentially improve upon injectable anti-angiogenic agents which are used to treat these diseases, but which may have limited efficacy," said Jai Balkissoon, MD, FACS, vice president of clinical development at Oxigene.
The company states that additional clinical testing with a more practical topical formulation potentially in combination with photodynamic therapy may be warranted.